Wire · opportunities
How BMS is Using NVIDIA AI to Discover New Drugs
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 July 2026 · Fusion42 review
Bristol Myers Squibb is deploying NVIDIA DGX SuperPOD infrastructure with 10x greater performance per megawatt to accelerate AI-driven drug discovery, supported by a strategic partnership with Anthropic to embed Claude agents across R&D, clinical development and manufacturing workflows.
This Wire brief sits within Fusion42's coverage of Digital Health, and 3 sources have reported it between 21 Jul 2026 and 27 Jul 2026.
◆ ◆ The Wire takeaway
If you sell to pharma R&D—molecule design tools, data integration, lab automation—BMS just proved the market will buy AI at industrial scale and embed it into core discovery loops. Your customer now has Claude agents and Vera Rubin compute as the baseline; you're competing against that or becoming a layer on top of it.
◆ Coverage
3 sources · first reported 21 Jul 2026 · latest 27 Jul 2026
◆ Related on Wire
◆ Topics